Protalix Biotherapeutics, Inc. insider trading

Every open-market purchase and sale by Protalix Biotherapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $101,360 1 trade by 1 insider 3 months later: median +23.7% (+28.1% vs S&P 500) Insider sales, 5 years $314 1 trade by 1 insider 3 months later: median +58.5% (+54.8% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Protalix Biotherapeutics, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Protalix Biotherapeutics, Inc.’s insiders pay?

From March 8, 2013 to December 23, 2025, 7 insiders reported 8 open-market purchases and 7 sales not made under a pre-set plan in Protalix Biotherapeutics, Inc. After sales, the shares moved −40.2% against the index over 12 months (a negative figure means selling was the right call).

Protalix Biotherapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Akirov Alfred	Director	0	—	—	4	−40.2% (4)	August 16, 2013
Bashan Dror	PRESIDENT AND CEO	3	—	—	0	—	December 23, 2025
Schwartz Aharon	Director	3	—	—	0	—	August 12, 2025
Camber Capital Management LP	10% owner	1	—	—	1	—	December 6, 2016
Bronfeld Zeev	Director	0	—	—	1	—	August 15, 2014
Manor Moshe	President & CEO	1	—	—	0	—	May 16, 2017
Oren Dan	10% owner	0	—	—	1	—	June 3, 2021

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Protalix Biotherapeutics, Inc. · Funds · Politicians